Drug Profile
Research programme: cancer therapeutics - Argenta/Janssen Pharmaceutica
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Argenta; Janssen Pharmaceutica
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom
- 31 Mar 2014 Argenta has been acquired by Charles River Laboratories
- 04 Oct 2010 Early research in Cancer in United Kingdom (unspecified route)